Hematologic toxicity of immune checkpoint inhibitors: real-world burden and risk profiles from a five-year cohort from the Middle East. Awada A, Tarhini A, Hammoud A, Kassem M, et al. BMC Cancer 2026;26:915.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Awada A, Tarhini A, Hammoud A, Kassem M, et al. Hematologic toxicity of immune checkpoint inhibitors: real-world burden and risk profiles from a five-year cohort from the Middle East. BMC Cancer 2026;26:915.
PMID: 42210190